Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166535 | 1.00 | EPHX2 (0.53) | EPHX2CNR1KDM5AKDM4CPHF8 | |
| SCHEMBL22021691 | 0.98 | EPHX2 (0.50) | EPHX2CNR1KDM5AKDM4CPHF8 | |
| SCHEMBL22021680 | 0.89 | EPHX2 (0.41) | EPHX2KDM5AKDM4CPHF8 | |
| SCHEMBL22021685 | 0.89 | EPHX2 (0.41) | EPHX2KDM5AKDM4CPHF8 | |
| SCHEMBL22021658 | 0.89 | EPHX2 (0.41) | EPHX2KDM5AKDM4CPHF8 | |
| SCHEMBL21456131 | 0.86 | CYP4F2 (0.42) | EPHX2CNR1KDM5AKDM4CPHF8 | |
| SCHEMBL21376559 | 0.85 | EPHX2 (0.36) | EPHX2CNR1ALDH1A1CES2CES1 | |
| SCHEMBL22021679 | 0.85 | EPHX2 (0.36) | EPHX2CNR1KDM5AKDM4CPHF8 | |
| SCHEMBL22021659 | 0.85 | EPHX2 (0.39) | EPHX2CNR1KDM5AKDM4CPHF8 | |
| SCHEMBL7939776 | 0.85 | EPHX2 (0.62) | EPHX2CNR1KDM5AKDM4CPHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | ACCUTAR BIOTECHNOLOGY INC. | 2021-07-15 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | CDK3, CDK4, CDK1 | EPHX2 1763/4885CNR1 844/4885KDM5A 790/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | EPHX2 1763/4885CNR1 844/4885KDM5A 790/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | EPHX2 896/4885CNR1 645/4885KDM5A 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.